# Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer

> **NCT00091286** · EARLY_PHASE1 · TERMINATED · sponsor: **Craig L Slingluff, Jr** · enrollment: 11 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine

## Key facts

- **NCT ID:** NCT00091286
- **Lead sponsor:** Craig L Slingluff, Jr
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-03-24
- **Primary completion:** 2008-02-15
- **Final completion:** 2008-02-15
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Slow accruals
- **Last updated:** 2020-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00091286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00091286, "Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00091286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*